MedTrace Logo

Drug Interaction Study Between AZD3355 and Nexium

NCT00684190 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

AZD3355

150 mg bid, oral, 7 days

DRUG

Esomeprazole

40 mg od, oral, 7 days

Sponsors & Collaborators

Principal Investigators

  • Eva Ersdal, PhD · AstraZeneca R&D, Mölndal, Sweden

  • Jan Vouis, MD · Quintiles AB, Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684190 on ClinicalTrials.gov